Darolutamide (Nubeqa)

This document provides detailed clinical guidance on the use of Darolutamide (Nubeqa®) in prostate cancer treatment, particularly focusing on its integration into medically integrated pharmacy (MIP) practices. It covers the clinical background of prostate cancer, the importance of multidisciplinary care, the expanded indication for Darolutamide, and the roles of healthcare providers in ensuring patient safety and adherence. The document emphasizes the importance of patient education and financial navigation in accessing therapy and highlights the effectiveness of team-based approaches in managing adverse events and optimizing treatment outcomes.